ES2879329T3 - Dipéptido imidazol para el tratamiento de la demencia debida al envejecimiento o la atrofia cerebral - Google Patents

Dipéptido imidazol para el tratamiento de la demencia debida al envejecimiento o la atrofia cerebral Download PDF

Info

Publication number
ES2879329T3
ES2879329T3 ES15768816T ES15768816T ES2879329T3 ES 2879329 T3 ES2879329 T3 ES 2879329T3 ES 15768816 T ES15768816 T ES 15768816T ES 15768816 T ES15768816 T ES 15768816T ES 2879329 T3 ES2879329 T3 ES 2879329T3
Authority
ES
Spain
Prior art keywords
agent
test
present disclosure
aging
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15768816T
Other languages
English (en)
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyushu University NUC
National Center of Neurology and Psychiatry
University of Tokyo NUC
NH Foods Ltd
Original Assignee
Kyushu University NUC
National Center of Neurology and Psychiatry
University of Tokyo NUC
NH Foods Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University NUC, National Center of Neurology and Psychiatry, University of Tokyo NUC, NH Foods Ltd filed Critical Kyushu University NUC
Application granted granted Critical
Publication of ES2879329T3 publication Critical patent/ES2879329T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/13—Dipeptidases (3.4.13)
    • C12Y304/1302—Beta-Ala-His dipeptidase (3.4.13.20)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
ES15768816T 2014-03-28 2015-03-04 Dipéptido imidazol para el tratamiento de la demencia debida al envejecimiento o la atrofia cerebral Active ES2879329T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014069103 2014-03-28
JP2014142910A JP2015193582A (ja) 2014-03-28 2014-07-11 イミダゾールジペプチドを含む剤
PCT/JP2015/056412 WO2015146522A1 (ja) 2014-03-28 2015-03-04 イミダゾールジペプチドを含む剤

Publications (1)

Publication Number Publication Date
ES2879329T3 true ES2879329T3 (es) 2021-11-22

Family

ID=54195052

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15768816T Active ES2879329T3 (es) 2014-03-28 2015-03-04 Dipéptido imidazol para el tratamiento de la demencia debida al envejecimiento o la atrofia cerebral

Country Status (8)

Country Link
US (2) US20170165314A1 (enExample)
EP (1) EP3124034B1 (enExample)
JP (1) JP2015193582A (enExample)
KR (2) KR20160146760A (enExample)
CN (1) CN106413733A (enExample)
ES (1) ES2879329T3 (enExample)
SG (2) SG11201608027RA (enExample)
WO (1) WO2015146522A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6401028B2 (ja) * 2014-11-27 2018-10-03 Ｓｈｉｏｄａライフサイエンス株式会社 鯨筋肉抽出物からなる中長期記憶障害予防改善剤
JP6550357B2 (ja) * 2016-08-24 2019-07-24 日本ハム株式会社 イミダゾールジペプチドを含有する、グリア細胞における神経栄養因子等の遺伝子の発現誘導剤
JP7134607B2 (ja) * 2016-08-25 2022-09-12 大正製薬株式会社 錠剤
JP6510004B2 (ja) * 2016-11-15 2019-05-08 日本ハム株式会社 イミダゾールジペプチドを含有するエクソソーム調節剤、およびエクソソームを含有する神経細胞活性化剤
JP2018140958A (ja) * 2017-02-28 2018-09-13 国立大学法人 東京大学 ペリサイトの変成を抑制する剤
US11148118B2 (en) * 2017-10-13 2021-10-19 W.M. Barr & Company, Inc. Encapsulated fragrance in compressed tablet
JP7251036B2 (ja) * 2018-06-28 2023-04-04 ポーラ化成工業株式会社 皮膚老化改善剤のスクリーニング方法
WO2020085459A1 (ja) * 2018-10-26 2020-04-30 国立大学法人東京大学 抗酸化剤、抗糖化剤又は抗炎症剤
JP7321017B2 (ja) * 2019-07-17 2023-08-04 東海物産株式会社 機能性食品
EP4081303A4 (en) * 2019-12-27 2024-01-24 Suntory Holdings Limited COMPOSITION CONTAINING A CYCLIC DIPEPTIDE, A PURINE NUCLEOSIDE AND/OR AN AMINO ACID AND A CHICKEN EXTRACT, METHOD FOR MANUFACTURING THE SAME, AND USE OF A CYCLIC DIPEPTIDE, A PURINE NUCLEOSIDE AND/OR AN AMINO ACID AND FROM CHICKEN EXTRACT
JP7523771B2 (ja) * 2020-02-26 2024-07-29 国立大学法人 東京大学 トランジスタ型センサ
EP4338267A4 (en) * 2021-05-14 2025-01-08 University of Rochester Variants of sirt6 for use in preventing and/or treating age-related diseases
KR102868976B1 (ko) * 2021-12-10 2025-11-03 (주)잇마플 생체이용율과 이미다졸 펩타이드가 증가된 수용성 닭가슴살 가수분해물 및 그 제조방법
WO2025104978A1 (ja) * 2023-11-13 2025-05-22 国立大学法人 東京大学 ネクロプトーシス制御剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960010020A (ko) * 1994-09-09 1996-04-20 도리이 신이치로 조혈 기능 항진제
EP2327404A1 (en) * 1994-11-08 2011-06-01 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
JP2000116987A (ja) 1998-10-15 2000-04-25 Sanyo Electric Co Ltd 洗剤溶かし装置およびこれを備えた洗濯機ならびに静止型溶解装置
JP4023648B2 (ja) 1999-01-13 2007-12-19 日本ハム株式会社 皮膚代謝促進物及び機能性食品
CA2389623A1 (en) * 1999-11-03 2001-05-10 Juvenon, Inc. Method of treating benign forgetfulness
KR20020044740A (ko) * 2000-12-06 2002-06-19 강경선 카노신을 유효성분으로 하는 세포예정사 관련 질환의 예방및 치료제
EP1285654B1 (en) * 2001-03-16 2006-06-07 Suntory Limited Autonomic system controlling agents and health drinks and foods
US6498498B1 (en) * 2001-06-27 2002-12-24 Intel Corporation Apparatus and method for applying reciprocity to frequency-domain noise analysis
WO2003013514A1 (en) * 2001-08-08 2003-02-20 Carn-Aware Llc Improving neurological functions
US20060257502A1 (en) * 2005-05-11 2006-11-16 Jiankang Liu A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders
JP2007070316A (ja) 2005-09-09 2007-03-22 Nippon Meat Packers Inc 経口用組成物及び栄養補助食品
JPWO2007116987A1 (ja) * 2006-03-31 2009-08-20 日本ハム株式会社 学習機能向上効果及び抗不安効果を有する機能性食品及び薬剤

Also Published As

Publication number Publication date
EP3124034A4 (en) 2018-03-21
WO2015146522A1 (ja) 2015-10-01
SG11201608027RA (en) 2016-11-29
KR20160146760A (ko) 2016-12-21
KR20220164079A (ko) 2022-12-12
US20180140655A1 (en) 2018-05-24
EP3124034A1 (en) 2017-02-01
JP2015193582A (ja) 2015-11-05
EP3124034B1 (en) 2021-04-21
US20170165314A1 (en) 2017-06-15
CN106413733A (zh) 2017-02-15
SG10201808208PA (en) 2018-10-30

Similar Documents

Publication Publication Date Title
ES2879329T3 (es) Dipéptido imidazol para el tratamiento de la demencia debida al envejecimiento o la atrofia cerebral
Gorissen et al. The muscle protein synthetic response to food ingestion
Wall et al. Dietary protein considerations to support active aging
JP6403039B2 (ja) Ｓｉｒｔ３およびｓｉｒｔ６の活性化剤
Chung et al. Improved cognitive performance following supplementation with a mixed-grain diet in high school students: a randomized controlled trial
JP2009528028A (ja) 哺乳類における健康状態を促進するためのレスベラトロールおよびその誘導体の使用
Cordeiro et al. Effects of fish protein hydrolysate ingestion on postexercise aminoacidemia compared with whey protein hydrolysate in young individuals
CN113398144B (zh) 核苷酸混合物在制备预防或缓解老年肌少症制剂中的应用
JP7101372B2 (ja) イミダゾールジペプチドを含む剤
JP6510004B2 (ja) イミダゾールジペプチドを含有するエクソソーム調節剤、およびエクソソームを含有する神経細胞活性化剤
JP2021531738A (ja) ケトン曝露を増加させるためのｍｃｔ製剤、並びにかかる製剤の製造及び使用方法
JP6478307B2 (ja) ミトコンドリア活性化剤
CN108463234A (zh) 星形胶质细胞的葡萄糖代谢激活剂
CN118338897A (zh) 使用氨基酸共混物用于在动物中提供健康益处的组合物和方法
CN101389321A (zh) 白藜芦醇及其衍生物用于改善哺乳动物健壮状态的用途
Karlic et al. Vegetarian diet affects genes of oxidative metabolism and collagen synthesis
Ahsan A Brief Overview and History of Human Nutrition and Health
JP2018030809A (ja) イミダゾールジペプチドを含有する、グリア細胞における神経栄養因子等の遺伝子の発現誘導剤
CN115697488A (zh) 用于改善认知功能的mct配制物
Doyle Case Report: Utilization of Urinary Neurotransmitter Metabolite Testing and Natural Supplements in the Management of Disordered Eating.
Pratto Burgos et al. Effects of Whey Protein, Carbohydrate, and Fibre Combination on Health Indicators: A Systematic Review
Ismaila et al. Quail Egg Yolk Oil Attenuates Insulin Resistance and Redox Imbalance in a High-Sugar-Diet Drosophila Model
WO2023188173A1 (ja) 脳内のｇａｂａ増加剤
BR102024023628A2 (pt) Preparo combinado para uso na melhora do estado muscular
Sawhney et al. Childhood Obesity: Reason behind this health crisis